Having trouble accessing articles? Reset your cache.

Medicines Co., SciClone deal

The Medicines Co. granted SciClone exclusive rights to promote cardiovascular drugs Cleviprex clevidipine and Angiomax bivalirudin

Read the full 162 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE